Study of IPG11406 for lupus kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called IPG11406 for people with active lupus nephritis, a type of kidney inflammation caused by lupus. It aims to see if the drug can help reduce kidney damage and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Weigh at least 45 kg (about 99 pounds)
- Have a lupus diagnosis with active kidney disease confirmed by a kidney biopsy within the last year
- Have a certain level of kidney protein in urine (UPCR > 1.0 g/g and 24-hour urine protein ≥ 1 g)
- Have specific blood test results showing high interferon-gamma and a Th1/Th2 ratio of 14 or more
- Not be pregnant or breastfeeding, and use effective birth control for 6 months after the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
This trial tests a new drug called SIM0278 for people with active lupus nephritis (kidney inflammation caused by lupus). It aims to see if adding this drug to standard treatment is safe and helpful for controlling the disease.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.